Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikolaj Torp

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Nature Reviews. Gastroenterology & Hepatology|December 5, 2024
The steatotic liver disease burden paradox: unravelling the key role of alcoholNikolaj Torp, Mads Israelsen, Aleksander Krag
Hepatology (Baltimore, Md.)|February 17, 2025
Letter to the Editor: Alcohol a confounding factor in the assessment of resmetirom therapyAleksander Krag, Nikolaj Torp, Mads Israelsen
Alimentary Pharmacology & Therapeutics|May 21, 2026
Editorial: Two Common Risks, One Greater Harm-Diabetes and Alcohol in Steatotic Liver DiseaseStine Johansen, Nikolaj Torp, Mads Israelsen, et al.
Gastroenterology|May 30, 2026
Reply to Ou and Xu and to Chang and MaoNikolaj Torp, Stine Johansen, Mads Israelsen, et al.
Alimentary Pharmacology & Therapeutics|August 23, 2025
Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice-Authors' ReplyNikolaj Torp, Mads Israelsen, Stine Johansen, et al.
The Lancet. Gastroenterology & Hepatology|January 24, 2025
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALDAleksander Krag, Nikolaj Torp, Zobair M Younossi, et al.
The Lancet. Gastroenterology & Hepatology|August 11, 2023
MetALD: new opportunities to understand the role of alcohol in steatotic liver diseaseMads Israelsen, Nikolaj Torp, Stine Johansen, et al.
The Lancet. Gastroenterology & Hepatology|June 10, 2023
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease - Authors' replyMads Israelsen, Nikolaj Torp, Stine Johansen, et al.
Annals of Hepatology|October 11, 2025
Limitations of MELD and MELD 3.0 for prognostication in patients with cirrhosis hospitalized with acute decompensation: an analysis of the ATTIRE trialNikolaj Torp, Nick Freemantle, Mads Israelsen, et al.
Journal of Hepatology|November 7, 2025
Limited clinical utility of serum-based ELISA PEth compared with whole-blood LC-MS/MS PEth to quantify alcohol consumptionNikolaj Torp, Mads Israelsen, Michael Estep, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Nature Reviews. Gastroenterology & Hepatology|December 5, 2024
The steatotic liver disease burden paradox: unravelling the key role of alcoholNikolaj Torp, Mads Israelsen, Aleksander Krag
Hepatology (Baltimore, Md.)|February 17, 2025
Letter to the Editor: Alcohol a confounding factor in the assessment of resmetirom therapyAleksander Krag, Nikolaj Torp, Mads Israelsen
Alimentary Pharmacology & Therapeutics|May 21, 2026
Editorial: Two Common Risks, One Greater Harm-Diabetes and Alcohol in Steatotic Liver DiseaseStine Johansen, Nikolaj Torp, Mads Israelsen, et al.
Gastroenterology|May 30, 2026
Reply to Ou and Xu and to Chang and MaoNikolaj Torp, Stine Johansen, Mads Israelsen, et al.
Alimentary Pharmacology & Therapeutics|August 23, 2025
Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice-Authors' ReplyNikolaj Torp, Mads Israelsen, Stine Johansen, et al.
The Lancet. Gastroenterology & Hepatology|January 24, 2025
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALDAleksander Krag, Nikolaj Torp, Zobair M Younossi, et al.
The Lancet. Gastroenterology & Hepatology|August 11, 2023
MetALD: new opportunities to understand the role of alcohol in steatotic liver diseaseMads Israelsen, Nikolaj Torp, Stine Johansen, et al.
The Lancet. Gastroenterology & Hepatology|June 10, 2023
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease - Authors' replyMads Israelsen, Nikolaj Torp, Stine Johansen, et al.
Annals of Hepatology|October 11, 2025
Limitations of MELD and MELD 3.0 for prognostication in patients with cirrhosis hospitalized with acute decompensation: an analysis of the ATTIRE trialNikolaj Torp, Nick Freemantle, Mads Israelsen, et al.
Journal of Hepatology|November 7, 2025
Limited clinical utility of serum-based ELISA PEth compared with whole-blood LC-MS/MS PEth to quantify alcohol consumptionNikolaj Torp, Mads Israelsen, Michael Estep, et al.
Pageof 5